[1] Sung H, Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71 (3):209-249. DOI:10.3322/caac. 21660.
[2] WHO.Global cancer observatory:cancer today,China [EB/OL].[2024-02-20].https://gco.iarc.who.int/media/ globocan/factsheets/populations/160-china-fact-sheet.pdf.
[3] 张海莲,张世超,于津浦,等.乳腺癌家系遗传易感基因研究进展[J].中国肿瘤临床,2018,45(21):1113-1116.
[4] 谷微,金狄,雷慧君,等.遗传性乳腺癌的筛查与预防[J/OL].肿瘤学杂志,1-8[2024-08-15].http://kns.cnki.net/kcms/detail/33.1266.R.20240718.1757.002.html.
[5] 吴海锋,武诗雅,孙涛. 中心性肥胖与疾病的关系及其 认定方法[J]. 生物学教学,2023,48(10):68-70. DOI:10.3969/j.issn.1004-7549.2023.10.028.
[6] Howe LR,Subbaramaiah K,Hudis CA, et al. Molecular pathways:adipose inflammation as a mediator of obesity associated cancer[J]. Clin Cancer Res, 2013, 19(22):6074-6083. DOI:10.1158/1078-0432.CCR-12-2603.
[7] Nicolini A,Carpi A,Rossi G. Cytokines in breast cancer [J]. Cytokine Growth Factor Rev, 2006, 17(5):325- 337. DOI:10.1016/j.cytogfr.2006.07.002.
[8] Feola A,Ricci S,Kouidhi S, et al. Multifaceted breast cancer:the molecular connection with obesity[J]. J Cell Physiol, 2017, 232(1):69-77. DOI:10.1002/jcp.25475.
[9] 张梅. BMI与乳腺癌临床病理特征的相关性研究[D]. 苏州:苏州大学,2021.DOI:10.27351/d.cnki.gszhu. 2021. 003738.
[10] Kabat GC, Kim MY, Lee JS, et al. Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women[J]. Cancer Epidemiol Biomarkers Prev,2017,26 (12):1730-1735.DOI:10.1158/1055-9965.EPI-17- 0495.
[11] World Cancer Research Fund/American Institute for Can-cer Research.Diet,Nutrition,Physical Activity and Can cer:a Global Perspective.Continuous Update Project Ex pert Report 2018[M].Washington DC:AICR,2018.Avai lable at dietandcancerreport.org.
[12] Gaudet MM,Gapstur SM,Sun J,et al.Active smoking and breast cancer risk:original cohort data and meta-analysis [J].J Natl Cancer Inst,2013,105(8):515-525.
[13] Collaborative Group on Hormonal Factors in Breast Can cer.Menarche,menopause,and breast cancer risk:indi vidual participant meta-analysis,including 118 964 women with breast cancer from 117 epidemiological studies[J].Lancet Oncol,2012,13(11):1141-1151.
[14] Collaborative Group on Hormonal Factors in Breast Can cer.Breast cancer and hormone replacement therapy:col laborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer[J].Lancet,1997,350(9084):1047-1059.
[15] Pizot C,Boniol M,Mullie P,et al.Physical activity,hor mone replacement therapy and breast cancer risk:a meta analysis of prospective studies[J].Eur J Cancer,2016,52:138-154.
[16] 乳腺癌诊疗指南(2022年版)[J].中国合理用药探索,2022,19(10):1-26.
[17] 王志鹏,马庆庆,余杰,等.肥胖对乳腺癌患者临床病理特征及预后的影响[J].中国肿瘤临床与康复,2024,31(04):218-224.DOI:10.13455/j.cnki.cjcor.113494-2024-2024-0110.
[18] 赫捷,陈万青,李霓等.中国女性乳腺癌筛查与早诊早治指南(2021,北京)[J].中国肿瘤,2021,30(03):161-191.
[19] 史斌浩,任敏.女性乳腺癌的主要危险因素[J].中国肿瘤外科杂志,2014,6(02):109-111.
[20] ANDERSEN L V B,LARSEN M J,DAVIES H,et al.Non BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness[J].Breast Cancer Res,2023,25(1):69.